GlennJHannaMD

Head & Neck Cancer, Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Dr. Hanna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3090

Fax+1 617-632-4448

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2016
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolInternship, Otolaryngology - Head and Neck Surgery, 2010 - 2011
Georgetown University School of MedicineClass of 2010

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Start of enrollment: 2018 Dec 05
Active, not recruiting
Phase 2
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Start of enrollment: 2019 Aug 05
Completed
Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Start of enrollment: 2020 Dec 24
Recruiting
Phase 2
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma Start of enrollment: 2030 Dec 18
Withdrawn
Phase 2
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial Start of enrollment: 2021 Dec 27
Recruiting
Not Applicable
Cemiplimab in AlloSCT/SOT Recipients With CSCC Start of enrollment: 2020 Nov 03
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
CIML NK Cell in Head & Neck Cancer Start of enrollment: 2020 Jul 20
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Drug Screening Using Novel IMD in ACC and Salivary Cancers Start of enrollment: 2023 Nov 01
Not yet recruiting
Early Phase 1
Roles: Contact, Principal Investigator
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC Start of enrollment: 2023 Jun 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Join now to see all

PubMed

Prospective Trial of Biomarker-Guided Surveillance for HPV-positive Oropharynx Cancer Using Plasma Tumor Tissue Modified Viral HPV DNA.
Eleni M Rettig, Jonathan D Schoenfeld, Julianna Miller, Bethany Sargent, Evan Carey
Clinical Cancer Research. 2024-12-26
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer.
Maryann Zhao, Jonathan D Schoenfeld, Ann Marie Egloff, Glenn J Hanna, Robert I Haddad
Nature Reviews. Clinical Oncology. 2024-12-10
1 citations
Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
Glenn J Hanna, Jamie Jabalee, John N Lukens, Lova Sun, Eleni M Rettig
Oral Oncology. 2024-11-01

Journal Articles

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Glenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
CIC‐NUTM1 Fusion: A Case Which Expands the Spectrum of NUT‐Rearranged Epithelioid Malignancies
Glenn J Hanna, Christopher A French, Genes, Chromosomes and Cancer

Lectures

An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who hav...
2019 ASCO Annual Meeting - 6/1/2019

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 DataNovember 20th, 2024
Higher Cancer Risk with Heavy Cannabis Use – US StudyAugust 21st, 2024
Heavy Cannabis Use May Increase Risk of Certain Cancers, New Study FindsAugust 8th, 2024
Join now to see all